E
42.52
-0.40 (-0.93%)
| Previous Close | 42.92 |
| Open | 42.92 |
| Volume | 1,783,265 |
| Avg. Volume (3M) | 2,988,730 |
| Market Cap | 11,595,544,576 |
| Price / Earnings (TTM) | 19.42 |
| Price / Earnings (Forward) | 21.46 |
| Price / Sales | 5.45 |
| Price / Book | 5.49 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 27.99% |
| Operating Margin (TTM) | 33.64% |
| Diluted EPS (TTM) | 2.19 |
| Quarterly Revenue Growth (YOY) | 30.60% |
| Quarterly Earnings Growth (YOY) | 327.70% |
| Total Debt/Equity (MRQ) | 8.78% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | 842.59 M |
| Levered Free Cash Flow (TTM) | 559.13 M |
| Return on Assets (TTM) | 18.05% |
| Return on Equity (TTM) | 30.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Exelixis, Inc. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | -1.5 |
| Insider Activity | 2.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.30 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.20% |
| % Held by Institutions | 94.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 31 Mar 2025 | 22,533,500 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (Citigroup, 31.70%) | Buy |
| Median | 46.00 (8.18%) | |
| Low | 38.00 (Stifel, -10.63%) | Hold |
| Average | 45.00 (5.83%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 42.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Jun 2025 | 47.00 (10.54%) | Buy | 41.43 |
| 27 Mar 2025 | 40.00 (-5.93%) | Buy | 36.84 | |
| B of A Securities | 05 Jun 2025 | 46.00 (8.18%) | Hold | 42.37 |
| Citigroup | 15 May 2025 | 56.00 (31.70%) | Buy | 46.26 |
| Morgan Stanley | 14 May 2025 | 47.00 (10.54%) | Buy | 44.65 |
| RBC Capital | 14 May 2025 | 40.00 (-5.93%) | Buy | 44.65 |
| Stifel | 14 May 2025 | 38.00 (-10.63%) | Hold | 44.65 |
| JMP Securities | 17 Apr 2025 | 41.00 (-3.57%) | Buy | 36.19 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ECKHARDT SUE GAIL | - | 42.88 | -18,838 | -807,773 |
| WYSZOMIERSKI JACK L | - | 42.67 | -7,535 | -321,518 |
| Aggregate Net Quantity | -26,373 | |||
| Aggregate Net Value ($) | -1,129,292 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 42.78 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director | 03 Jun 2025 | Automatic sell (-) | 7,535 | 42.67 | 321,518 |
| ECKHARDT SUE GAIL | Director | 02 Jun 2025 | Automatic sell (-) | 18,838 | 42.88 | 807,773 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |